Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Total Current Liabilities (2012 - 2026)

Kamada's (KMDA) quarterly Total Current Liabilities came in at $49.2 million in Q2 2026, up 7.4% on a YoY basis from $45.8 million in Q2 2025, and down 17.76% quarter-over-quarter from $59.8 million in Q1 2026.

Analysis

Kamada (KMDA) Total Current Liabilities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Total Current Liabilities for 13 consecutive years, with $49.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Current Liabilities rose 7.4% year-over-year to $49.2 million; the trailing twelve-month figure through Jun 2026 stood at $49.2 million (up 7.4% YoY), and the FY2025 full-year result was $47.4 million, down 4.04% from the prior year.
  • Total Current Liabilities slipped to $49.2 million in Q2 2026 per KMDA's latest filing, from $59.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $75.7 million in Q4 2022 and bottomed at $34.0 million in Q3 2024.
  • Historically, Total Current Liabilities has averaged $51.5 million across 5 years, with a median of $49.3 million in 2024.
  • The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 160.07% in 2022, then tumbled 46.34% in 2024.
  • Over 5 years, Total Current Liabilities stood at $75.7 million in 2022, then sank by 34.49% to $49.6 million in 2023, then decreased by 0.41% to $49.4 million in 2024, then retreated by 4.04% to $47.4 million in 2025, then rose by 3.72% to $49.2 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods registered $49.2 million, $59.8 million, and $47.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Amgen 211.39 Bn 197.40 Bn 7.24 Bn 25.50 Bn
2 Gilead Sciences 181.14 Bn 177.96 Bn 6.22 Bn 11.02 Bn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn 3.94 Bn
4 Regeneron Pharmaceuticals 82.91 Bn 74.91 Bn 3.93 Bn 5.53 Bn
5 Argenx Se 61.55 Bn 56.36 Bn 1.37 Bn 1.58 Bn
6 Moderna 54.39 Bn 49.25 Bn 52.00 Mn 2.53 Bn
7 Alnylam Pharmaceuticals 34.43 Bn 31.12 Bn 992.69 Mn 1.51 Bn
8 Biogen 31.18 Bn 29.89 Bn 1.96 Bn 3.92 Bn
9 Roivant Sciences 30.11 Bn 30.11 Bn 1.16 Mn 283.60 Mn
10 Kamada 472.70 Mn 402.57 Mn 22.47 Mn 49.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 49.16 Mn
Mar 31, 2026 59.78 Mn
Dec 31, 2025 47.39 Mn
Sep 30, 2025 47.84 Mn
Jun 30, 2025 45.77 Mn
Mar 31, 2025 57.05 Mn
Dec 31, 2024 49.39 Mn
Sep 30, 2024 34.00 Mn
Jun 30, 2024 40.90 Mn
Mar 31, 2024 37.18 Mn
Dec 31, 2023 49.59 Mn
Sep 30, 2023 37.27 Mn
Jun 30, 2023 65.83 Mn
Mar 31, 2023 69.28 Mn
Dec 31, 2022 75.71 Mn
Sep 30, 2022 69.15 Mn
Jun 30, 2022 49.68 Mn
Mar 31, 2022 42.23 Mn
Dec 31, 2021 54.06 Mn
Sep 30, 2021 26.59 Mn